| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate |
2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2007-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2007517019-A |
| titleOfInvention |
Method for treating multiple sclerosis |
| abstract |
Use of an A3 adenosine receptor agonist in the preparation of a pharmaceutical composition for treating an individual suffering from multiple sclerosis. The composition is preferably administered orally. Also disclosed is a pharmaceutical composition for treating multiple sclerosis comprising an effective amount of an A3 adenosine receptor agonist and a pharmaceutically acceptable carrier. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012144512-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5565784-B2 |
| priorityDate |
2003-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |